PaperTrail for Clinicians
A clinical-evidence companion that turns the latest journals in a specialty (oncology, cardiology, pediatrics) into weekly briefings with cited claims, sample sizes and a 'ready for your team meeting' summary.
Time-pressed clinicians and clinical pharmacists who need to stay current without reading 200 abstracts a week
- Weekly specialty briefing with cited claims, effect sizes and a 'clinical bottom line' per paper
- Patient-context view: ask 'what's new for stage-2 HER2+ patients' and get cited papers
- Journal-club slide generator with citations pre-formatted for PowerPoint/Keynote
- Push alerts when a guideline-cited paper is retracted or corrected
Citation-complete mining stacks are mature enough on GitHub (Nemotron + Qdrant) to wrap into specialty clinical workflows where provenance is regulated
Multiple competing products already live and serving the same audience (MedBriefs, MediSummary, Monday Clinical Brief, NEJM Clinician, Read by QxMD), confirming real demand from time-pressed clinicians.The Monday Clinical Brief — Weekly Journal Digests for Clinicians ↗MedBriefs — Evidence-Based Clinical Briefs for Physicians ↗
Saturated market: at least five direct competitors (MedBriefs at $4.99/mo, MedBriefs.ai, MediSummary, Monday Clinical Brief, NEJM Clinician) plus incumbents Read by QxMD, Consensus, Elicit — leaving little differentiated whitespace for a new entrant without a unique angle.MedBriefs — Evidence-Based Clinical Briefs for Physicians ↗NEJM Clinician | Concise Summaries of Medical Research & Guidelines ↗Featured Papers | Read by QxMD ↗
Willingness-to-pay is real but thin — MedBriefs charges only $4.99/mo and MediSummary uses a freemium subscription; clinical/medical disclaimers (e.g., MedBriefs.ai explicitly excluding clinical use) limit premium positioning and force low-touch DTC pricing.MedBriefs — Evidence-Based Clinical Briefs for Physicians ↗MedBriefs.ai — Verified Medical Research Briefings from PubMed ↗
Clinical evidence review is a durable, regulation-adjacent need; however, the Nature/PMC hallucination-safety literature (Asgari et al.) is actively shaping compliance expectations, creating a moving regulatory target.A framework to assess clinical safety and hallucination rates of LLMs for medical text summarisation ↗
Nemotron+Qdrant citation stack is technically mature, but clinical-grade accuracy plus mandatory disclaimers, HIPAA considerations, and the documented high hallucination/omission rates in medical summarisation make a trusted specialty briefing product materially harder than a generic research tool.Hallucination Rates in Medical AI: What the Citation Fabrication Data Tells Us ↗